Clinical Report: Epidermal Biomarker Resolves Tricky Skin Lesions

Overview

A study presented at ECP 2026 demonstrated that epidermal CD271 expression significantly outperformed traditional markers Ki67 and PRAME in diagnosing challenging melanocytic lesions.

Background

Diagnosing melanocytic lesions is a complex task that often challenges even experienced pathologists. Traditional immunohistochemical markers like Ki67 and PRAME are useful but have limitations in specificity and sensitivity.

Data Highlights

Key Findings

• CD271 expression in basal keratinocytes was consistent in benign nevi but disrupted in melanomas.
• CD271 outperformed Ki67 and PRAME in diagnostic performance with a ROC curve of 0.93.
• The study involved 156 challenging melanocytic lesions assessed through immunohistochemical staining.
• Statistically significant differences were observed across benign, intermediate, and malignant lesion classes.

Clinical Implications

The use of CD271 as a biomarker may enhance the diagnostic process for challenging melanocytic lesions.

Conclusion

The study highlights the potential of CD271 in improving the diagnostic accuracy of melanocytic lesions.

Related Resources & Content

1. Patricia Switten Nielsen, ECP 2026 -- Epidermal Biomarker Resolves Tricky Skin Lesions
2. the pathologist — (AI) Skin in the Game
3. MDSpire News — Nonblistering Papules: Genetic Mystery Cracked
4. MDSpire News — New Biomarkers Reveal Topical Treatment Effects
5. the pathologist — Pathology: What’s In the News?
6. AI Skin in the Game
7. Nonblistering Papules: Genetic Mystery Cracked
8. New Biomarkers Reveal Topical Treatment Effects
9. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10. Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma - PMC
11. NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation - PMC